The inflammatory action of NSAIDs is attributed to the inhibition of cyclooxygenase (COX), and consequently, the conversion of arachidonic acid into prostaglandins (PGs). It is hypothesized that the undesirable side effects of NSAIDs are associated with the inhibition of COX-1 (constitutive isoform), whereas the beneficial effects are related to the inhibition of COX-2 (inducible isoform).
The inflammatory action of NSAIDs is attributed to the inhibition of cyclooxygenase (COX), and consequently, the conversion of arachidonic acid into prostaglandins (PGs). It is hypothesized that the undesirable side effects of NSAIDs are associated with the inhibition of COX-1 (constitutive isoform), whereas the beneficial effects are related to the inhibition of COX-2 (inducible isoform).
While COX-2 selective inhibitors seem to be safer than non-selective NSAID with regard to gastrointestinal damage, 5) they decrease vascular prostacyclin (PGI 2 ) production and may affect the balance between pro-thrombotic and anti-thrombotic eicosanoids.
6) The decrease of vasodilatory and anti-aggregatory PGI 2 production may tip the balance in favor of pro-thrombotic eicosanoids such as thromboxane A2 and may cause increase of cardiovascular thrombotic events. 7) Due to these possibly serious cardiovascular side effects, the manufacturer of rofecoxib, the first COX-2 selective NSAID, decided to voluntarily withdraw the drug from the market in 2004, and other drugs in the same category are under close review thereafter. This event brought significant impact on clinicians and patients, and many of them are seeking for alternative medication. 8) Therefore, NSAID which exhibits less gastrointestinal and cardiovascular side effects have earned a major interest from many medicinal chemists as a new option for the management of diseases that requires long-term use of the anti-inflammatory medications. Compounds that simultaneously inhibit cyclooxygenase and 5-lipoxygenase (5-LOX) have received attention from medicinal chemists because inhibition of 5-LOX blocks the production of LTB4, a leucotriene, which plays an important role in the development of gastrointestinal ulcers.
1)
Recently, we have synthesized 17 compounds which had dual inhibition of COX and 5-LOX. 9) Among the 17 prepared compounds, 1-furan-2-yl-3-pyridine-2-yl-propenone (FPP-3) demonstrated the most significant dual COX/5-LOX inhibitory activity. 9) Chemical structure of FPP-3 is shown in Fig. 1 . We further investigated the effect of the compound on other pro-inflammatory cytokines and demonstrated that FPP-3 decreased expression of nitric oxide synthase and production of tumor necrosis factor-a in vitro. 10) In this study, we examined the effects of the propenone compound, FPP-3, on the pharmacokinetics of theophylline, a commonly prescribed medication for the patients with asthma or chronic obstructive pulmonary disease. We also studied cytochrome P450 activity test to investigate drug interaction of FPP-3 with theophylline because CYP 1A is a predominant enzyme for the metabolism of the latter.
MATERIALS AND METHODS
Materials Theophylline, 7-(b-hydroxypropyl)-thephylline, ethoxyresorufin, and methoxyresorufin obtained from Sigma. 2-Acetylfuran and 2-pyridinecarboxaldehyde, acetonitrile, dichloromethane, sodium phosphate monobasic, and sodium phosphate dibasic were purchased from Sigma-Aldrich. All other chemicals were analytical grade and were used without further purification. Thin-layer chromatography (TLC) and column chromatography were performed with Kieselgel 60 F 254 (Merck) and silica gel Kieselgel 60 (230-240 mesh, Merck), respectively. Compounds were visualized on TLC plates with UV light and r-anisaldehyde solution. Nuclear magnetic resonance (NMR) spectra were taken on a Bruker AMX 250 MHz, and tetramethylsilane was used as an internal standard. Chemical shifts (d ) were recorded in ppm, and coupling constants (J ) in Hz.
Synthesis of 1-Furan-2-yl-3-pyridine-2-yl-propenone The synthetic procedure of FPP-3 was detailed elsewhere. 9, 10) Briefly, sodium hydroxide (34 mg) was added to a solution of 2-acetylfuran (5.0 ml, 49.9 mmol) and 2-pyridinecarboxaldehyde (5.2 ml, 54.9 mmol) in absolute ethanol (30 ml) under nitrogen at 25°C, and the mixture was vigorously stirred at 25°C for 3 h. Water (80 ml) was added to the solution to quench the reaction. The mixture was extracted with CH 2 Cl 2 (120 ml) and the organic layer was washed with water (80 ml, 2 times) and saturated aqueous NaCl solution (80 ml), and dried with Na 2 SO 4 . The solvent was evaporated under reduced pressure and the residue was purified by silica gel column chromatography with an elution of ethyl acetate and hexane (EtOAc : n-hexaneϭ1 : 2, v/v) to give FPP-3 (3.84 g) as a yellow crystal in 38.7% yield. The purity of this compound was above 99% when analyzed by HPLC and 1 H-NMR.
Animal Study Seven-week-old male Sprague Dawley rats weighing approximately 250 g were supplied by OrientBio (Seoul, Korea) and housed in groups not exceeding six per cage and maintained under standard conditions. Food and tap water were available ad libitum. The acclimation period was one week before the experimental procedure with a dark/light cycle of 12 : 12 at a temperature of 23Ϯ2°C. Animal experiments were carried out according to the guidelines for animal use in toxicology and current Korean laws when the experiment was carried out.
Rats were randomly separated into three test groups and a control group. Three days before the administration of theophylline, rats in each test group began to be pretreated with oral administration of FPP-3 suspended in corn oil. Doses of FPP-3 ranged from 17 to 68 mg/kg. Rats in the control group received the same amount of corn oil without the drug. On the fourth day, all rats were co-administered with intravenous (penile vein) dose of theophylline solution in 0.9% saline (3.0 mg/ml). The dose of theophylline was fixed to 3 mg/kg of body weight of rats. Blood samples of 0.3 ml were serially withdrawn under anesthesia via subclavian vein into small heparinized Eppendorf tubes at prior to, 0.25, 0.5, 1, 2, 4, 6, and 8 h after theophylline injection. The blood samples were immediately centrifuged at 2000 rpm for 7 min, and the plasma was taken out and stored at Ϫ20°C until HPLC assay. Statistical analysis was performed using the SPSS 12.0 program.
Cytochrome P450 Activity Enzyme activities of cytochrome P450 1A2 and 1A1 were measured using methoxyresorufin-O-demethylase (MROD) and ethoxyresorufin-O-deethylase (EROD) activity assays, respectively. MROD and EROD activities were determined from the rate of formation of resorufin from either methoxyresorufin or ethoxyresorufin as described by Blank et al. with a slight modification.
11) FPP-3 (0, 1, 5, 10 mM) was preincubated with rat liver microsomes for 5 min at 37°C. The formation of resorufin was monitored by fluorescence spectroscopy at excitation and emission wavelengths of 550 and 585 nm, respectively. Statistical analysis was performed using the SPSS 12.0 program.
HPLC Assay of Theophylline in Plasma Concentration of theophylline in plasma sample was assayed by HPLC with a slight modification on the method described by Koch et al. 12) The frozen plasma samples were thawed at room temperature and aliquots of 100 ml were spiked with 50 ml of internal standard (7-b-hydroxypropyl-theophylline in ethanol, 25 mg/ml). After a few seconds of vortex-mixing, 1.8 ml of methylene chloride was added for deproteination of the plasma sample. Precipitation of the protein was facilitated by centrifugation using Eppendorf microcentrifuge for 1 min at 13000 g and the resultant clear supernatant (1 ml) was transferred to Eppendorf tube and dried in vacuum using centrifugal evaporator. The dried residue was reconstituted by 200 ml of mobile phase (mixture of 0.05 M phosphate buffer and acetonitrile (81 : 19), pH 5.0) and injected to HPLC system (Shimadzu, Japan) by using autoinjector (Intelligent Sampler AS-950-10, Jasco, Japan).
The plasma level of unmetabolized theophylline was assayed by the HPLC system equipped with Class VP computer software, LC 10AD VP pump, and SPD 10A VP UV-VIS detector at 274 nm. Column was Inertsil ODS-3 (4.6ϫ150 mm, GL Science Inc, Japan) and mobile phase consisted of a mixture of 0.05 M phosphate buffer (sodium phosphate monobasic and sodium phosphate dibasic) and acetonitrile (81 : 19, v/v) adjusted to pH 5.0 with phosphoric acid. Flow rate was 0.8 ml/min and the injection volume of the sample was 20 ml. Before measuring the plasma level of theophylline by HPLC, validation of the assay was performed by repeating five times a day for five consecutive days using exactly same condition in the range of 57.10, 88.90, 454.5, 833.3, 1154, and 1429 ng/ml. The pharmacokinetic parameters were calculated using the software WinNonlin Standard Edition Version 1.1 by non-compartmental method.
RESULTS AND DISCUSSION
Validation of HPLC assay was performed by repeating five times a day on the first day and for five consecutive days. Limit of quantification (LOQ) was 57.10 ng/ml and precisions of intra-day and inter-day at the LOQ were 14.27% and 13.47%, respectively. Accuracies of intra-day and inter-day were within about (15%, showing an acceptable variation for the quantification of theophylline in rat plasma sample. Linearity of calibration curve for determination of theophylline was r 2 ϭ0.9996 in the range of from 57.10 to 1429 ng/ml. The retention times for theophylline and internal standard were 3.6 min and 4.9 min, respectively. Table 1 summarized the pharmacokinetic parameters of theophylline in rat following a single intravenous administration of 3 mg/kg theophylline. The pharmacokinetic parameters of theophylline did not change significantly when the drug was intravenously administered after three consecutive days of pretreatment with 17 mg/kg, orally, of FPP-3. However, there were significant changes on the pharmacokinetic parameters of the drug when rats were pretreated with 34 or 68 mg/kg FPP-3 for the same period and theophylline was administered thereafter. The plasma concentration of theophylline in rat at 0.25 h was 1.72Ϯ0.14 mg/ml following a single intravenous administration of the drug without FPP-3. In contrast, the concentrations were 2.52Ϯ0.38 and 3.16Ϯ 0.26 mg/ml when the drug was administered after pretreatment with 34 and 68 mg/kg FPP-3, respectively. These changes represent about 46% and 84% increases in comparison to the plasma level of the control group in the corresponding order. There were even more remarkable changes in the areas under the curve during the first 8 h (AUC 0-8 ), showing increases of about 70% and 130% in the pretreatment groups, compared to the AUC 0-8 of theophylline without FPP-3 pretreatment. The half life of theophylline was 2.2 h and it was delayed to 4.4 h when the rats were pretreated with 68 mg/kg FPP-3. Significant decreases of volumes of distribution (V d ) were also observed dose-dependently when FPP-3 was co-administrated with theophylline. It appears that FPP-3 affects the protein binding of theophylline as well as inhibition of metabolism of the drug. Fig. 2 shows concentration versus time profiles of theophylline in our pharmacokinetic study.
We reported that FPP-3 inhibited the production of nitric oxide synthase and tumor necrosis factor-a in vitro in addition to inhibition of COX and 5-LOX activity. 10) Furthermore, we have found that FPP-3 was a substrate of enzymes of rat liver microsomes and cytosols in vitro. 13) In this study, therefore, we have investigated cytochrome P450 activity to see whether the altered pharmacokinetic parameters are related with the enzyme activity of cytochrome P450 1A, which is predominantly responsible for the metabolism of theophylline. 14, 15) The concentration range of FPP-3 was selected based on the previous report 9) of the in vitro 50% inhibitory concentration (1.89 mM) of FPP-3 for inhibition of COX-2 activity together with our preliminary experiment result of peak plasma concentration of FPP-3 after dosing of the investigatory drug to rats (0.95, 1.68, and 3.06 mM after a single oral dose of 17, 34, and 68 mg/kg, respectively). The result of cytochrome P450 activity test showed that the activity of the enzyme was decreased by FPP-3 in vitro. MROD test revealed that the relative activity of cytochrome P450 1A2 was dose-dependently reduced to 69.6, 36.8, and 20.1% in the presence of 1, 5, and 10 mM FPP-3 concentrations, respectively (Fig. 3) . EROD test also demonstrated that the relative activity of cytochrome P450 1A1 was dose-dependently decreased in the presence of FPP-3. Cytochrome P450 1A2 is enzyme that is responsible for the metabolism of theophylline: demethylation to both 1-methylxanthine and 3-methylxanthine. Based on this result, it is considered that the alteration in pharmacokinetic parameters of theophylline after pretreatment with 34 and 68 mg/kg FPP-3 is due to the inhibitory effect of FPP-3 on cytochrome P450 1A family.
The therapeutic dose range of FPP-3 is not available at this point since we have not performed a dose-finding study of the investigatory drug. Fortunately, in this study, pretreatment with 17 mg/kg, orally, of FPP-3 for three consecutive days did not change the pharmacokinetic parameters of theophylline in rats. Therefore, it is suggested that the dose range of FPP-3 be less than 17 mg/kg to avoid drug interaction with other drugs which are metabolized by cytochrome P450 1A family. Cytochrome P450 1A plays an important role in the 1284 Vol. 29, No. 6 metabolism of various medications such as amitriptyline, fluvoxamine, and theophylline, which are frequently prescribed for geriatric patients. [16] [17] [18] Inhibition or induction of cytochrome P450 enzyme system is a major cause of drug interaction, and the drug interaction issue constitutes one of the most important adverse drug event for geriatric patients who often take several medications simultaneously.
Taking into consideration that FPP-3 is intended to be primarily used by geriatric patients with chronic diseases and therefore is highly prone to long-term use of the drug, the investigatory drug needs to be assessed in terms of drug interaction with other commonly prescribed medications. Especially in the wake of Vioxx ® (rofecoxib), investigatory drugs should be extensively evaluated in various perspectives. Drug interaction issue should be an example of those perspectives.
CONCLUSION
The pharmacokinetic parameters of theophylline did not change significantly when the drug was intravenously administered after three consecutive days of pretreatment with 17 mg/kg, orally, of FPP-3 while there were significant changes in doses of 34 and 68 mg/kg FPP-3. The alteration in pharmacokinetic parameters of theophylline appears to be due to the inhibitory effect of FPP-3 on cytochrome P450 1A, which is responsible for the metabolism of theophylline. Considering that FPP-3 is intended to be primarily used by geriatric patients with chronic diseases and therefore is highly prone to long-term use, the investigatory drug needs to be extensively evaluated in terms of drug interaction with other commonly prescribed medications.
